|
Display # |
|
1 |
PubMed
|
186 |
|
2 |
Influenza
Mice treated with THC and infected with influenza.
|
203 |
|
3 |
Fortune Magazine Article
|
871 |
|
4 |
CB2 Ligands
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630
|
476 |
|
5 |
Tocris Biosciences, Inc.
A scientific supply house which is the only source for research scientists to obtain L759,656 and L759,633.
|
169 |
|
6 |
L759,633
L759,633 is one of two classical cannabinoids developed by MerckFrosst which is an excellent CB2 ligand.
|
355 |
|
7 |
L759,656
L759,656 is one of two classical cannabinoids developed by MerckFrosst which is an excellent CB2 ligand.
|
319 |
|
8 |
Cannabinoid Receptor Data
Tocris Bioscience is one of the largest suppliers of cannabinoid receptor ligands. Most of the compounds are available to researchers without a special DEA permit.
|
329 |
|
9 |
Earnst & Young
Economic conditions.
|
1894 |
|
10 |
Macrophage Inhibition
Cannabinoid Inhibition of Macrophage Migration to the Trans-Activating (Tat) Protein of HIV-1
|
370 |
|
11 |
Autoimmune Uveoretinitis
The cannabinoid agonist JWH 133 has a high in vivo, anti-inflammatory property and may exert its effect via inhibiting the activation and function of autoreactive T cells and preventing leukocyte trafficking into the inflamed tissue.
|
243 |
|
12 |
Activation of murine macrophages
Macrophages infected with TMEV (Theiler's virus) increased IL-12p40 production and activation of CB2 receptors by JWH-133 (100 nM) inhibited it.
|
231 |
|
13 |
Endocannabinoid System protects glioma cells against Tat
The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation.
|
520 |
|
14 |
CB2 Receptor on Monocyte Migration
Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration.
|
200 |
|
15 |
Inhibition of monocyte migration
Selective activation of CB2 receptors modulates chemotaxis of human monocytes, which might have crucial effects in chronic inflammatory disorders such as atherosclerosis or rheumatoid arthritis.
|
214 |
|
16 |
CB2 modulates the CXCL12/CXCR4-mediated chemotaxis
The CB(2)-selective agonist JWH-015, caused a significant inhibition of the chemokine CXCL12-induced and CXCR4-mediated chemotaxis of Jurkat T cells, as well as their transendothelial migration.
|
204 |
|
17 |
Temporal variation in CB2R levels
Resting T lymphocytes do not detectably express either the cannabinoid receptor-1 (CB(1)R) or CB(2)R at the protein level. However, CB(2)R protein expression is upregulated in a biphasic manner in T lymphocytes following activation by superantigen.Interestingly, both 2-AG and JWH-133 inhibited CXCL12-induced chemotaxis, suggesting a modulatory role for cannabinoids in activated T lymphocytes.
|
453 |
|
18 |
CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced
The CB2 agonists, JWH-133 and HU-308, dose-dependently attenuated the effects of TNF-alpha on vascular smooth muscle proliferation and migration.
|
209 |
|
19 |
Macrophages in vaginal mucosa
Macrophages in vaginal mucosa are permissive to HIV infection with their monocyte-like expression of CD4, CCR5 and CXCR4 receptors. In addition, vaginal macrophages also support R5 replication which indicates that vaginal macrophages may be important target cells in the genital transmission of HIV-1 and genital HIV-1 infection.
|
297 |
|
20 |
The HIV Drug Development Pipeline
"Quad" Tablet vs. Atripla; GS 9350 (Cobicistat) vs. Ritonavir. There is a concern about kidney toxicity but at this time testing showed that cobicistat impaired secretion of creatinine which is a measure of kidney function rather than causing damage.
|
855 |
|
Page 1 of 2 |
